

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
31 July 2003 (31.07.2003)

PCT

(10) International Publication Number  
WO 03/061645 A1(51) International Patent Classification<sup>7</sup>: A61K 31/196,  
A61P 29/00WOOD, Jeanette, Marjorie [NZ/CH]; In den Kleematten  
18, CH-4105 Biel-Benken (CH).

(21) International Application Number: PCT/EP03/00612

(74) Agent: GROS, Florent; Novartis AG, Corporate Intellectual Property, Patent and Trademark Department, CH-4002 Basel (CH).

(22) International Filing Date: 22 January 2003 (22.01.2003)

(25) Filing Language:

English

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(30) Priority Data:  
0201520.4 23 January 2002 (23.01.2002) GB

(84) Designated States (regional): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR).

(71) Applicant (for all designated States except AT, US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments


For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (for AT only): NOVARTIS PHARMA GMBH [AT/AT]; Brunner Strasse 59, 1235 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BRAZZELL, Romulus, Kimbro [US/US]; 9705 Foxworth Drive, Alpharetta, GA 30201 (US). LAMBROU, George, N. [FR/FR]; 76, rue de Mulhouse, F-68300 St. Louis (FR). LATOUR, Elisabeth [FR/FR]; 26F, rue de Bâle, F-68870 Bartenheim-La Chaussée (FR). OTTLECZ, Anna [US/CH]; Pilgerstrasse 16, CH-4055 Basel (CH).

(54) Title: PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS



(57) Abstract: The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrobulbar fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, and R<sub>5</sub> are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug esters thereof.


PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS

This invention relates to selective cyclooxygenase-2 inhibitors (COX-2 Inhibitors), in particular to the use of COX-2 inhibitors in the treatment of angiogenesis-related ocular diseases such as ocular neovascular disease, e.g., retinal neovascularization and choroidal neovascularization.

COX-2 inhibitors and their use as non-steroidal anti-inflammatory drugs (NSAIDs) for the treatment of inflammatory diseases and pain are well known in the art. Further it has been proposed (see for instance USP 6,025,353, Searle) to use COX-2 inhibitors to treat angiogenesis related disorders including ophthalmic conditions such as corneal graft rejection, ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, diabetic retinopathy, retrobulbar fibroplasias, and neovascular glaucoma.

It has now been found that certain COX-2 inhibitors, in particular 5-alkyl substituted 2-arylaminophenylacetic acid derivative COX-2 inhibitors, have desirable properties for use in the treatment of ocular neovascular disease.

Accordingly the invention provides a method of treating an angiogenesis-mediated ocular disorder in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I



wherein *R* is methyl or ethyl;

- 2 -

R<sub>1</sub> is chloro or fluoro;

R<sub>2</sub> is hydrogen or fluoro;

R<sub>3</sub> is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;

R<sub>4</sub> is hydrogen or fluoro; and

R<sub>5</sub> is chloro, fluoro, trifluoromethyl or methyl;

a pharmaceutically acceptable salt thereof; or

a pharmaceutically acceptable prodrug ester thereof.

Further the invention provides the use of a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) as defined above for the preparation of a medicament, for use in the treatment of an angiogenesis-mediated ocular disorder.

In a further aspect the invention provides use of a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) as defined above for the treatment of an angiogenesis-mediated ocular disorder.

In a yet further aspect the invention provides an ocular angiogenesis inhibiting or reversing agent comprising a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) as defined above as active ingredient.

In a still yet further aspect the invention provides a package comprising a compound of formula I (or pharmaceutically acceptable salt or prodrug ester thereof) as defined above together with instructions for use in the treatment of an angiogenesis-mediated ocular disorder.

Angiogenesis-mediated ocular disorders which may be treated according to the invention include ocular diseases and disorders which directly or indirectly involve angiogenesis or neovascularisation, such as ocular neovascularisation, choroidal neovascularisation, retinal neovascularisation, including ischemic retinopathies in general, neovascularisation following injury or infection, retrobulbar fibroplasias, and neovascular

glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME) and herpes keratitis.

In the present description the terms "treatment" or "treat" refer to both prophylactic or preventative treatment as well as curative or disease modifying treatment, including treatment of patients at risk of contracting the disease or suspected to have contracted the disease as well as patients who are ill or have been diagnosed as suffering from a disease or medical condition.

Particularly preferred compounds of formula I are those wherein R is methyl or ethyl; R<sub>1</sub> is chloro or fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen, fluoro, chloro, methyl or hydroxy; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro, fluoro or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable esters thereof.

A particularly preferred embodiment relates to the compounds of formula I wherein R is methyl or ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen, fluoro or hydroxy; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Another particularly preferred embodiment of the invention relates to compounds of formula I wherein R is ethyl or methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen or fluoro; R<sub>3</sub> is hydrogen, fluoro, ethoxy or hydroxy; R<sub>4</sub> is hydrogen or fluoro; and R<sub>5</sub> is chloro, fluoro or methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Further are said compounds wherein R is methyl or ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub>-R<sub>4</sub> are hydrogen or fluoro; and R<sub>5</sub> is chloro or fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

A further embodiment of the invention relates to the compounds of formula I wherein R is methyl or ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is fluoro; R<sub>3</sub> is hydrogen, ethoxy or hydroxy; R<sub>4</sub> is fluoro; and R<sub>5</sub> is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Another embodiment of the invention relates to the compounds of formula I wherein R is methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen or fluoro; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.


Particularly preferred embodiments of the invention relate to compounds of formula I

- (a) wherein R is methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is hydrogen; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof;
- (b) wherein R is methyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is fluoro; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is chloro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof;
- (c) wherein R is ethyl; R<sub>1</sub> is fluoro; R<sub>2</sub> is fluoro; R<sub>3</sub> is hydrogen; R<sub>4</sub> is fluoro; and R<sub>5</sub> is fluoro; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof; and
- (d) wherein R is ethyl; R<sub>1</sub> is chloro; R<sub>2</sub> is hydrogen; R<sub>3</sub> is chloro; R<sub>4</sub> is hydrogen; and R<sub>5</sub> is methyl; pharmaceutically acceptable salts thereof; and pharmaceutically acceptable prodrug esters thereof.

Most preferably 5-methyl-2-(2'-chloro-6'-fluoroanilino)-phenylacetic acid or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug thereof is used as the COX-2 inhibitor of the invention.

Pharmacologically acceptable salts of the compounds of formula I are preferably salts with bases, conveniently metal salts derived from groups Ia, Ib, IIa and IIb of the Periodic Table of the Elements, including alkali metal salts, e.g. potassium and especially sodium salts, or alkaline earth metal salts, preferably calcium or magnesium salts, and also ammonium salts with ammonia or organic amines.

Pharmaceutically acceptable prodrug esters of the compounds of formula I are ester derivatives which are convertible by solvolysis or under physiological conditions to the free carboxylic acids of formula I. Such esters are e.g. lower alkyl esters (such as the methyl or ethyl ester), carboxy-lower alkyl esters such as the carboxymethyl ester, nitrooxy-lower alkyl esters (such as the 4-nitrooxybutyl ester), and the like. Preferred prodrugs are the compounds of formula Ia



wherein R and R<sub>1</sub>-R<sub>5</sub> have meaning as defined hereinabove for compounds of formula I; and pharmaceutically acceptable salts thereof.

Compounds of formula I and Ia and their synthesis are described in published international patent applications Nos. WO 99/11605 and WO 01/23346, the teachings of which are incorporated herein by reference,

The COX-2 inhibitor compounds of formula I and pharmaceutically acceptable salts and esters thereof, are preferably used in the form of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with excipients or carriers suitable for

either enteral, parenteral or topical application. In addition, they may also contain other therapeutically valuable substances. The compositions may be prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1 to 90%, preferably about 1 to 60%, of the active ingredient.

Pharmaceutical compositions comprising the compounds of formula I may be, for example, compositions for enteral, such as oral, rectal, aerosol inhalation or nasal administration; compositions for parenteral, such as intravenous or subcutaneous administration; compositions for transdermal administration (e.g. passive or iontophoretic), or compositions for topical administration,

Preferably, the pharmaceutical compositions comprising the compounds of formula I are adapted to oral or topical administration.

The particular mode of administration and the dosage may be selected by the attending physician taking into account the particulars of the patient, especially age, weight, life style, activity level, etc .

Preferred oral forms are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g. silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and or polyvinylpyrrolidone; if desired d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Tablets may be either film coated or enteric coated according to methods known in the art.

Suitable injectable compositions are aqueous isotonic solutions or suspensions, and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing,

wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers.

Suitable formulations for transdermal application include an effective amount of a compound of the invention with carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. For example, transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with carriers, optionally a rate controlling barrier to deliver the compound of the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.

Preferred formulations for topical application, e.g. to the skin and eyes, include aqueous solutions, suspensions, ointments, creams, gels or sprayable formulations, for example, for delivery by aerosol or the like. Such topical formulations typically contain from about 0.1 up to about 50% by weight, preferably from about 1 up to about 20% by weight of COX-2 inhibitor compound.

The dosage of COX-2 inhibitor administered is dependent on the subject, the body weight, age and individual condition, and on the form of administration. A unit dosage for oral administration to a mammal of about 50 to 70 kg weight may contain between about 5 and 2000 mg, e.g. from 100-800 mg, preferably 200-400 mg of the active ingredient. When the COX-2 inhibitor is 5-methyl-2-(2'-chloro-6'-fluoro-anilino)-phenyl acetic acid, or a pharmaceutically acceptable salt thereof, an appropriate dose is in the range from 100 to 1500 mg of 5-methyl-2-(2'-chloro-6'-fluoro-anilino)-phenyl acetic acid daily, for example, 200-1000 mg/day, such as 200, 400, 500, 600, 800, 900 or 1000 mg/day, administered in one or two doses daily.

Parenteral formulations are especially injectable fluids that are effective in various manners, such as intravenously, intramuscularly, intraperitoneally, intranasally, intradermally or subcutaneously.

Pharmaceutical compositions comprising compounds of formula I for use in accordance with invention are conveniently supplied in the form of a package comprising the composition, e.g. as a single dose or multiple doses thereof or as a reservoir of composition for repeated application (e.g. for topical application), together with written instructions or other indications (e.g. a package insert) for use in the treatment of an angiogenesis-mediated ocular disorder.

The Compounds of formula I may be used with other antiangiogenic agents including bisphosphonates, e.g. ibandronate, alendronate or zoledronate and salts and esters thereof, EGFR antagonists.

Preferred embodiments of the instant invention include uses, methods and packages as described above, wherein the compound of formula (I), in particular 5-methyl-2-(2'-chloro-6'-fluoroanilino)-phenylacetic acid, pharmaceutically acceptable salts thereof; or pharmaceutically acceptable prodrug esters thereof, is in the form of an oral composition and the angiogenesis-mediated ocular disorder is preferably selected from age-related macular degeneration, diabetic retinopathy and diabetic macular edema, more preferably from age-related macular degeneration and diabetic retinopathy.

The ocular antiangiogenic properties of compounds of formula I may be demonstrated using suitable procedures and animal models; for instance, as described below

#### Drug treatment of mice with ischemic retinopathy

Ischemic retinopathy is produced in C57/BL6J mice by the following method: Seven-day-old mice and their mothers are placed in an airtight incubator and exposed to an atmosphere of  $75 \pm 3\%$  oxygen for 5 days. Incubator temperature is maintained at  $23 \pm 2^\circ\text{C}$ , and oxygen is measured every 8 hours with an oxygen analyzer. After 5 days, the mice are removed from the incubator, placed in room air, and COX-2 inhibitor drug treatment is begun. Drugs are diluted in phosphate-buffered saline (PBS) or 1% dimethyl sulfoxide depending upon their solubility characteristics and then diluted to their final concentration with PBS.

Vehicle (control) or vehicle containing various concentrations of drug (volume = 50 µl in neonates and 100 µl in adult mice) is placed in the stomach by gavage. After 5 days of treatment at P17, mice are sacrificed, eyes are rapidly removed and frozen in optimum cutting temperature embedding compound (OCT; Miles Diagnostics, Elkhart, IN) or fixed in 10% phosphate-buffered formalin and embedded in paraffin. Adult C57BL6J mice are also treated by gavage with drug or vehicle and after 5 days, they are sacrificed and their eyes are processed for frozen or paraffin sections.

#### Quantitation of retinal neovascularization

Frozen sections (10 µm) of eyes from drug-treated and control mice are histochemically stained with biotinylated griffonia simplicifolia lectin B4 (Vector Laboratories, Burlingame, CA) which selectively binds to endothelial cells. Slides are incubated in methanol/H<sub>2</sub>O<sub>2</sub> for 30 minutes at 4°C, washed with 0.05 M TBS, and incubated for 30 minutes in 10% normal porcine serum. Slides are rinsed with 0.05M Tris-buffered saline, pH 7.6 (TBS) and incubated 2 hours at room temperature with biotinylated lectin. After being rinsed with 0.05M TBS, slides are incubated with avidin coupled to peroxidase (Vector Laboratories) for 45 minutes at room temperature. After being washed for 10 minutes with 0.05 M TBS, slides are incubated with diaminobenzidine to give a brown reaction product. Some slides are counterstained with hematoxylin and all are mounted with Cytoseal.

To perform quantitative assessments, 10 µm serial sections are cut through the entire extent of each eye. The entire eye is sampled by staining sections roughly 50-60 µm apart, which provided 13 sections per eye for analysis. Lectin-stained sections are examined with an Axioskop microscope (Zeiss, Thornwood, NY) and images are digitized using a 3 CCD color video camera (IK-TU40A, Toshiba, Tokyo, Japan) and a frame grabber. Image-Pro Plus software (Media Cybernetics, Silver Spring, MD) is used to delineate lectin-stained cells on the surface of the retina and their area is measured. The mean of the 13 measurements from each eye is used as a single experimental value.

Drug treatment of mice during retinal vascular development

Litters of newborn C57/BL6J mice are divided into treatment and control groups which received daily subcutaneous injections of 10 mg/kg of drug or vehicle, respectively. At P7 or P10, mice are anesthetized with ether, and perfused with 1 ml of phosphate-buffered saline containing 50 mg/ml of fluorescein-labeled dextran ( $2 \times 10^6$  average mw, Sigma, St. Louis, MO).. The eyes are removed and fixed for 1 hour in 10% phosphate-buffered formalin. The cornea and lens are removed and the entire retina is carefully dissected from the eyecup, radially cut from the edge of the retina to the equator in all 4 quadrants, and flat-mounted in Aquamount with photoreceptors facing upward. Flat-mounts are examined by fluorescence microscopy and images are digitized using a 3 CCD color video camera (IK-TU40A, Toshiba, Tokyo, Japan) and a frame grabber. Image-Pro Plus software (Media Cybernetics, Silver Spring, MD) is used to measure the distance from the center of the optic nerve to the leading front of developing retinal vessels in each quadrant and the mean is used as a single experimental value.

Drug treatment of mice with choroidal neovascularization

Choroidal neovascularization is generated by modification of a previously described technique. Briefly, 4 to 5 week old male C57BL/6J mice are anesthetized with ketamine hydrochloride (100 mg/kg body weight) and the pupils are dilated with 1% tropicamide. Three burns of krypton laser photocoagulation (100  $\mu\text{m}$  spot size, 0.1 seconds duration, 150 mW) are delivered to each retina using the slit lamp delivery system of a Coherent Model 920 Photocoagulator and a hand held cover slide as a contact lens. Burns are performed in the 9, 12, and 3 o'clock positions of the posterior pole of the retina. Production of a bubble at the time of laser, which indicates rupture of Bruch's membrane, is an important factor in obtaining CNV, so only mice in which a bubble is produced for all three burns are included in the study. Ten mice are randomly assigned to treatment with vehicle alone and 10 mice received vehicle containing 120 $\mu\text{moles}/\text{kg}/\text{day}$  of one of the test drugs given orally by gavage. After 14 days, the mice are killed with an overdose of pentobarbital sodium, and their eyes are rapidly removed and frozen in optimal cutting temperature embedding compound (OCT).

Quantitation of choroidal neovascularization

Frozen serial sections (10 µm) are cut through the entire extent of each burn and histochemically stained with biotinylated griffonia simplicifolia lectin B4 (Vector Laboratories, Burlingame, CA), which selectively binds to endothelial cells. Slides are incubated in methanol/H<sub>2</sub>O<sub>2</sub> for 30 minutes at 4°C, washed with 0.05 M TBS, and incubated for 30 minutes in 10% normal swine serum. Slides are rinsed with 0.05M TBS and incubated 2 hours at 37°C with biotinylated lectin. After being rinsed with 0.05M TBS, slides are incubated with Streptavidin-phosphatase (Kirkegaard and Perry Laboratories, Cabin John, MD) for 30 minutes at room temperature. After a 10 minute wash in 0.05 M Tris buffer, pH 7.6, slides are developed in Histomark Red (Kirkegaard and Perry) to give a red reaction product, and mounted with Cytoseal (Stephens Scientific, Riverdale, NJ). Some slides are counterstained with Contrast Blue (Kirkegaard and Perry).

To perform quantitative assessments, lectin-stained sections are examined with an Axioskop microscope (Zeiss, Thornwood, NY) and images are digitized using a 3 CCD color video camera (IK-TU40A, Toshiba, Tokyo, Japan) and a frame grabber. Image-Pro Plus software (Media Cybernetics, Silver Spring, MD) is used to delineate and measure the area of lectin-stained blood vessels in the subretinal space. For each lesion, area measurements are made for all sections on which some of the lesion appeared and added together to give the integrated area measurement. Values are averaged to give one experimental value per mouse. A 2-sample t-test for unequal variances is performed to compare the log mean integrated area between treatment and control mice.

Compounds of formula I inhibit ocular angiogenesis when tested in the models described above.

The following examples are intended to illustrate the invention and are not to be construed as being limitations thereon.

- 12 -

### EXAMPLES

#### A. Formulation Examples

##### Example 1

Table 1

<b>Ingredient</b>	<b>Amount per 200 mg tablet batch (kg)</b>
<b>Core</b>	
<b>Granulation</b>	
5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid drug substance	50**
Microcrystalline cellulose, NF (PH 101)	12.85
Lactose monohydrate, NF	11.65
Croscarmellose sodium, NF	1
Povidone, USP	4
Titanium dioxide, USP	2
Water, purified ***, USP	20.375
<b>Extra-granular Phase</b>	
Microcrystalline cellulose, NF (PH 102)	13
Croscarmellose sodium, NF	3
Titanium dioxide, USP	2
Magnesium stearate, NF	0.5
<b>Coating</b>	
Opadry white	2.801 ****
Opadry yellow	2.0 ****
Opadry red	0.4 ***
Opadry black	0.0504 ****
Water, purified ***, USP	29.758 ****

\*\* The weight of drug substance is taken with reference to the dried substance (100 per cent) on the basis of the assay value (factorization). The difference in weight is adjusted by the amount of microcrystalline cellulose used.

\*\*\* Removed during processing.

\*\*\*\* Includes a 50 % excess for loss during the coating process.

Table 1, above, sets out the formula for a batch of approximately 250,000 immediate release film-coated tablets of 5-methyl-2-(2'-chloro-6'-fluoroanilino)-phenylacetic acid. To make the tablets, titanium dioxide is dispersed in water, followed by the addition of povidone and mixing for 20 minutes to make a povidone/titanium dioxide suspension. The drug substance, lactose, microcrystalline cellulose, and croscarmellose are mixed in a high shear mixer (e.g., a Collette Gral) for 5 minutes to form a drug mixture. The drug mixture is granulated in the high shear mixer with the povidone/titanium dioxide suspension. The suspension is pumped at a rate of 3 kg/min into the drug mixture. The resulting mixture is mixed an additional 90 seconds after all the suspension is added. The wet granulation is dried in a fluid bed dryer, using an inlet air temperature of 50 °C. The residual water target is 3.5 % (with a permissible range of 2.5 – 4.5 %). The dried granulation is passed through a screen using a mill (oscillator) and a 30 mesh screen. The previous steps are repeated to make a second granulation.

The extra-granular phase titanium dioxide is passed through a 60 mesh hand screen. The dry granulations are mixed with the extra-granular phase microcrystalline cellulose, croscarmellose sodium and titanium dioxide in a twin shell mixer for 300 revolutions to form a penultimate mixture. Magnesium stearate is passed through a 60 mesh hand screen and is mixed with the penultimate mixture in a twin shell mixer for 50 revolutions to form a tableting mixture. The tableting mixture is pressed into tablets using a tablet press and oval punches.

The coating powders (Opadry) are mixed with purified water to make a 15 % w/w coating suspension. The tablets are film coated with the coating suspension in a coating pan using 60 °C to 75 °C inlet air temperature.

Table 2 sets out the contents of a 200 mg 5-methyl-2-(2'-chloro-6'-fluoroanilino)-phenylacetic acid film-coated tablet.

**Table 2**

<b>Ingredient</b>	<b>Theoretical amount [mg]</b>	<b>Function</b>
<b>Core</b>		
5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid	200	Active substance
drug substance		
Microcrystalline cellulose (PH 101)	51.4	Filler
Lactose	46.6	Filler
Povidone	16	Binder
Titanium dioxide	8	Color
Croscarmellose sodium	4	Disintegrant
Water, purified *	Q.S.	Granulating liquid
<b>Extrgranular phase</b>		
Microcrystalline cellulose (PH 102)	52	Filler
Croscarmellose sodium	12	Disintegrant
Titanium dioxide	8	Color
Magnesium stearate	2	Lubricant
<b>Core weight</b>	<b>400</b>	
<b>Coating</b>		
Opadry white (00F18296)	7.4676	Color
Opadry yellow (00F12951)	5.3312	Color
Opadry red (00F15613)	1.0668	Color
Opadry black (00F17713)	0.1344	Color
Water, purified *	Q.S.	Coating solvent
<b>Total weight</b>	<b>414</b>	

\* removed during processing

In addition, the tablet formulations may contain 5-methyl-2-(2'-chloro-6'-fluoroanilino)benzyl alcohol and/or 5-methyl-2-(2'-chloro-6'-fluoroanilino)benzoic acid in an amount between about 0.01 and 2% by weight, more specifically between about 0.1 and 1

Example 2

An alternative formulation is as set out in Table 3, with information about as percentage w/w, mg/dose, and kg/ 50,000 tablet batch.

Table 3 Alternative formulation composition

% w/w	Ingredient	Mg/dose	Kg/batch
Granulation			
65.04	5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid drug substance	400.00	20.00
2.15	Croscarmellose sodium, NF (Ac-Di-Sol)	13.22	0.661
6.60	Povidone K30, USP	40.59	2.029
18.12	Purified water, USP*	Qs	Qs
Blending			
23.56	Microcrystalline Cellulose, NF (Avicel PH 102)	144.90	6.066
2.15	Croscarmellose sodium, NF (Ac-Di-Sol)	13.22	0.553
0.50	Magnesium Stearate, NF (vegetable source)	3.07	0.128
Film Coating			
84.46	Opadry, Global White 00F18296	15.2028	0.296637
14.03	Opadry, Global Red 00F15613	2.5254	0.049275
1.51	Opadry, Global Black 00F17713	0.2718	0.005303
	Purified Water, USP*	Qs	1.990218
Film Coated Tablet Weight			633.00

\*Does not appear in final product. Percentage of water added used for granulation based on the dry weight of drug substance and croscarmellose sodium.

The batch is granulated as described in Example 1. The granulation is dried to residual moisture (% LOD) of 1.79%. The formulation process is the same as for the development batches as described above, except for the additional step of coating with Opadry in a coating pan. The coating powders (Opadry) are mixed with purified water to make a 15 % w/w coating suspension. The tablets are film coated with the coating suspension in a coating pan using 60°C to 75°C inlet air temperature. Based on friability data, a target force of 18 KN (16 – 20 KN range) is used to compress the remainder of the batch, resulting in acceptable friability (less than 0.5%) and the disintegration times of less than 5 mins. The ejection force is approximately 800 N throughout the compression run. This demonstrates that the blend is lubricated adequately. No picking/sticking is observed on the punch surfaces after 225 minutes. Thus, a smaller size tablet with high drug loading (65%) is achieved using a high shear granulation process, using 17 X 6.7 mm ovaloid tooling to get tablets with acceptable hardness and friability characteristics.

In addition, the tablet formulations may contain 5-methyl-2-(2'-chloro-6'-fluoroanilino)benzyl alcohol and/or 5-methyl-2-(2'-chloro-6'-fluoroanilino)benzoic acid in an amount between about 0.01 and 2% by weight, more specifically between about 0.1 and 1%.

### Example 3

#### Wet granulated tablet composition

<u>Amount per tablet</u>	<u>Ingredient</u>
25 mg	COX-2 inhibitor
79.7 mg	Microcrystalline cellulose
79.7 mg	Lactose monohydrate
6 mg	Hydroxypropyl cellulose
8 mg	Croscarmellose sodium
0.6 mg	Iron oxide
1 mg	Magnesium stearate

- 17 -

Tablet dose strengths of between 5 and 125 mg can be accommodated by varying total weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose: lactose monohydrate.

Example 4

Directly compressed tablet composition

<u>Amount per tablet</u>	<u>Ingredient</u>
25 mg	COX-2 inhibitor
106.9 mg	Microcrystalline cellulose
106.9 mg	Lactose anhydride
7.5 mg	Croscarmellose sodium
3.7 mg	Magnesium stearate

Tablet dose strengths of between 5 and 125 mg can be accommodated by varying total tablet weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose:lactose monohydrate.

Example 5

Hard gelatine capsule composition

<u>Amount per capsule</u>	<u>Ingredient</u>
25 mg	COX-2 inhibitor
37 mg	Microcrystalline cellulose
37 mg	Lactose anhydride
1 mg	Magnesium stearate
1 capsule	Hard gelatin capsule

Capsule dose strengths of between 1 and 50 mg can be accommodated by varying total fill weight, and the ratio of the first three ingredients. Generally it is preferable to maintain a 1:1 ratio for microcrystalline cellulose:lactose monohydrate.

Example 6

Oral solution

Amount per 5mL Ingredient

50 mg COX-2 inhibitor  
to 5 mL with Polyethylene oxide 400

Example 7

Oral suspension

Amount per 5mL dose Ingredient

101 mg COX-2 inhibitor  
150 mg Polyvinylpyrrolidone


Oral suspensionAmount per 5mL dose Ingredient

2.5 mg Poly oxyethylene sorbitan monolaurate  
10 mg Benzoic acid  
to 5 mL with sorbitol solution (70%)

Suspension dose strengths of between 1 and 50 mg/5 ml can be accommodated by varying the ratio of the first two ingredients.

Example 8Intravenous infusionAmount per 200 mL dose      Ingredient

1 mg COX-2 inhibitor  
0.2 mg Polyethylene oxide 400  
1.8 mg Sodium chloride  
to 200 mL      Purified water

**CLAIMS****1. Use of a compound of formula I**

wherein

R is methyl or ethyl;

R<sub>1</sub> is chloro or fluoro;

R<sub>2</sub> is hydrogen or fluoro;

R<sub>3</sub> is hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy or hydroxy;

R<sub>4</sub> is hydrogen or fluoro; and

R<sub>5</sub> is chloro, fluoro, trifluoromethyl or methyl;

or a pharmaceutically acceptable salt or prodrug ester thereof,

in the preparation of a medicament for use in the treatment of an angiogenesis-mediated ocular disorder.

2. A method of treating an angiogenesis-mediated ocular disorder in a subject in need of such treatment which comprises administering to the subject an effective amount of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt or prodrug ester thereof.
3. A package comprising a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt or prodrug ester thereof, together with instructions for use in the treatment of an angiogenesis-mediated ocular disorder.

- 20 -

4. Use according to claim 1 or method according to claim 2 or package according to claim 3, in which the compound of formula I is 5-methyl-2-(2-chloro-6-fluoroanilino)-phenylacetic acid or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable prodrug ester thereof.
5. Use according to claim 1 or method according to claim 2 or package according to claim 3, wherein the angiogenesis-mediated ocular disorder is selected from ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrothalic fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, diabetic macular edema, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME) and herpes keratitis.
6. Use according to claim 1 or method according to claim 2 or package according to claim 3, wherein the compound of formula I is in the form of an oral composition.
7. Use according to claim 1 or method according to claim 2 or package according to claim 3, wherein the compound of formula I is in the form of a topical composition.
8. Use or method or package according to claim 6, wherein the angiogenesis-mediated ocular disorder is selected from age-related macular degeneration, diabetic retinopathy and diabetic macular edema.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00612

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 7 A61K31/196 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, PASCAL, MEDLINE, EMBASE, SCISEARCH, BIOSIS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 11605 A (NOVARTIS AG) 11 March 1999 (1999-03-11) cited in the application page 5, line 27 -page 6, line 4 page 21, line 1-5; claims ----	1-7
A	US 3 652 762 A (PFISTER RUDOLF ET AL) 28 March 1972 (1972-03-28) the whole document ----	1-8 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

Date of the actual completion of the International search

30 May 2003

Date of mailing of the International search report

05/06/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Venturini, F

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00612

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MOSER P ET AL: "SYNTHESIS AND QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS OF DICLOFENAC ANALOGUES" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 33, 1990, pages 2358-2368, XP001024801 ISSN: 0022-2623 the whole document ---	1-8
P,A	WO 02 20090 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); GIMONA ALBERTO (CH) 14 March 2002 (2002-03-14) the whole document ---	1-8
P,A	WO 03 020261 A (NOVARTIS ERFIND VERWALT GMBH ; NOVARTIS AG (CH); BATEMAN SIMON DAVI) 13 March 2003 (2003-03-13) the whole document -----	1-8

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No

PCT/EP 03/00612

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9911605	A	11-03-1999	AT	237580 T	15-05-2003
			AU	743371 B2	24-01-2002
			AU	9534098 A	22-03-1999
			BR	9812010 A	12-12-2000
			CN	1268112 T	27-09-2000
			DE	69813570 D1	22-05-2003
			WO	9911605 A1	11-03-1999
			EP	1007505 A1	14-06-2000
			JP	2001514244 T	11-09-2001
			NO	20000943 A	25-02-2000
			NZ	502669 A	01-02-2002
			PL	338357 A1	23-10-2000
			RU	2186762 C2	10-08-2002
			SK	2472000 A3	12-09-2000
			TR	200000447 T2	21-07-2000
			US	6291523 B1	18-09-2001
			US	2002183391 A1	05-12-2002
			US	6310099 B1	30-10-2001
			US	2002013369 A1	31-01-2002
			ZA	9807785 A	01-03-1999
			HU	0002514 A2	28-12-2000
US 3652762	A	28-03-1972	NONE		
WO 0220090	A	14-03-2002	AU	1390002 A	22-03-2002
			WO	0220090 A2	14-03-2002
			NO	20031095 A	10-03-2003
			US	2002061932 A1	23-05-2002
WO 03020261	A	13-03-2003	WO	03020261 A1	13-03-2003